Eli Lilly and Co logo

Eli Lilly and Co (LLY)

Market Closed
13 Mar, 20:00
737. 80
-14.4
-1.91%
- Market Cap
104.2 P/E Ratio
5.2% Div Yield
12 Volume
6.64 Eps
752.2
Previous Close
Day Range
737.8 753.9
Year Range
650 886.5
Earnings results expected in 46 days

Summary

LLY closed today lower at €737.8, a decrease of 1.91% from yesterday's close, completing a monthly decrease of -5.53% or €43.2. Over the past 12 months, LLY stock lost -1.03%.
LLY pays dividends to its shareholders, with the most recent payment made on Mar 10, 2025. The next estimated payment will be in In 2 months on Jun 10, 2025 for a total of €1.5.
The last earnings report, released on Feb 04, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.41%, based on the last three reports. The next scheduled earnings report is due on Apr 28, 2025.
The stock of the company had never split.
The company's stock is traded on 16 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

LLY Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Eli Lilly and Co Dividends

Eli Lilly and Co logo
LLY 3 weeks ago
Estimated
Other
€1.44 Per Share
Eli Lilly and Co logo
LLY 3 weeks ago
Other
€1.44 Per Share
Eli Lilly and Co logo
LLY 3 months ago
Other
€1.25 Per Share
Eli Lilly and Co logo
LLY 6 months ago
Other
€1.25 Per Share
Eli Lilly and Co logo
LLY 9 months ago
Other
€1.25 Per Share
Eli Lilly and Co logo
LLY 14 Feb 2024
Other
€1.25 Per Share

Eli Lilly and Co Earnings

28 Apr 2025 (46 Days) Date
-
Cons. EPS
-
EPS
4 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
8 Aug 2024 Date
2.7
Cons. EPS
3.92
EPS
6 May 2024 Date
-
Cons. EPS
-
EPS
Eli Lilly and Co logo
LLY 3 weeks ago
Estimated
Other
€1.44 Per Share
Eli Lilly and Co logo
LLY 3 weeks ago
Other
€1.44 Per Share
Eli Lilly and Co logo
LLY 3 months ago
Other
€1.25 Per Share
Eli Lilly and Co logo
LLY 6 months ago
Other
€1.25 Per Share
Eli Lilly and Co logo
LLY 9 months ago
Other
€1.25 Per Share
Eli Lilly and Co logo
LLY 14 Feb 2024
Other
€1.25 Per Share
28 Apr 2025 (46 Days) Date
-
Cons. EPS
-
EPS
4 Feb 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
-
EPS
8 Aug 2024 Date
2.7
Cons. EPS
3.92
EPS
6 May 2024 Date
-
Cons. EPS
-
EPS

Eli Lilly and Co (LLY) FAQ

What is the stock price today?

The current price is €737.80.

On which exchange is it traded?

Eli Lilly and Co is listed on NYSE.

What is its stock symbol?

The ticker symbol is LLY.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Apr 28, 2025.

Has Eli Lilly and Co ever had a stock split?

No, there has never been a stock split.

Eli Lilly and Co Profile

Drug Manufacturers—General Industry
Healthcare Sector
Mr. David A. Ricks CEO
XSTU Exchange
US5324571083 ISIN
United States Country
43,000 Employees
14 Feb 2025 Last Dividend
- Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000